Monopar Therapeutics (MNPR) Stock Forecast & Price Target

Monopar Therapeutics is attractive because ALXN1840 now has a stronger regulatory path, with a rolling NDA submission already underway, Fast Track, Orphan Drug, and Rare Pediatric Disease designations, and a potentially meaningful non-dilutive Priority Review Voucher opportunity of roughly $100M. The clinical package is compelling, as the Phase 3 FoCus trial showed rapid and sustained copper mobilization versus standard of care over 48 weeks, while 645 patient-years of follow-up in 266 patients support durable use and a well-characterized safety profile with 4.9% drug-related serious adverse events and no treatment-related deaths. The thesis is further reinforced by EASL and EAN data showing neurological improvement, global clinical benefit, and liver stabilization in heavily pre-treated Wilson disease patients, alongside a pipeline that also includes Phase 1-stage radiopharmaceutical imaging and treatment programs for uPAR-expressing cancers.

Monopar Therapeutics is a highly speculative clinical-stage biopharmaceutical company whose value depends heavily on ALXN1840 and early radiopharmaceutical assets, leaving it exposed to binary trial outcomes, regulatory delays, and the possibility that the FDA may demand additional mechanistic studies before approval. Even with a recent NDA rolling submission and reported supportive data readouts, commercial adoption remains uncertain because Wilson disease already has multiple marketed or in-development therapies, and physicians may be slow to change prescribing habits or reimbursement may fail to materialize. The company also faces meaningful financial risk, including the need for additional equity financing to complete development, while larger competitors with greater R&D and commercial resources could further limit market potential.